You just read:

Frost & Sullivan Publishes Update Coverage Report on BiolineRx Ltd.: Continued advancement and execution of BiolineRx's lead oncology project - BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15

News provided by

Frost & Sullivan

26 Mar, 2018, 12:21 BST